LH vs MYGN
LH: A global diagnostics and drug development laboratory leader that performs 750+ million clinical tests annually and supports 85% of new FDA-approved drugs through comprehensive testing capabilities. MYGN: Myriad Genetics is a molecular diagnostics and precision medicine company that develops genetic tests for cancer screening, therapy selection, prenatal health, and mental health to guide clinical decisions and improve patient outcomes.
Side-by-side fundamentals
| Metric | LH | MYGN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $281.46 | $5.66 | |
| Market cap as of 2026-07-23 | $23.1B | $547M | |
| P/E as of 2026-07-23 | 24.51 | n/a | |
| PEG as of 2026-07-23 | 2.76 | -0.00 | MYGN lower |
| Net margin as of 2026-07-23 | +6.7% | -48.2% | LH higher |
| Gross margin as of 2026-07-23 | +28.8% | +70.0% | MYGN higher |
| Operating margin as of 2026-07-23 | +10.2% | -46.9% | LH higher |
| ROE as of 2026-07-23 | +10.9% | -109.1% | LH higher |
| ROA as of 2026-07-23 | +5.1% | -57.4% | LH higher |
| Debt / equity as of 2026-07-23 | 0.73 | 0.36 | MYGN lower |
| Revenue growth (YoY) as of 2026-07-23 | +7.3% | -0.3% | LH higher |
| Revenue CAGR (3y) SEC XBRL | +5.6% | +6.7% | MYGN higher |
| Dividend yield as of 2026-07-23 | +1.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | n/a | |
| Beta as of 2026-07-23 | 0.88 | 1.62 | |
| 1-year return as of 2026-07-22 close | +11.7% | +23.3% | MYGN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.